The real-world use of medicines for the management of haematological malignancies in paediatric populations : a scoping review

Tools

Alkhlaifat, Rahaf and Madanat, Faisal and Abunimeh, Hanan Nabeel and Weir, Natalie M. and Mueller, Tanja (2025) The real-world use of medicines for the management of haematological malignancies in paediatric populations : a scoping review. Expert Review of Anticancer Therapy. ISSN 1744-8328 (https://doi.org/10.1080/14737140.2025.2610260)

[thumbnail of Alkhlaifat-etal-ERAT-2025-The-real-world-use-of-medicines-for-the-management-of-haematological-malignancies]
Preview
 Text. Filename: Alkhlaifat-etal-ERAT-2025-The-real-world-use-of-medicines-for-the-management-of-haematological-malignancies.pdf
Final Published Version
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo
Download (1MB)| Preview

Abstract

There is limited research on the real-world use of medicines for the management of pediatric cancers, with insufficient understanding of the varied approaches toward treatment across the globe. This scoping review aimed to identify publications focusing on systematic anti-cancer therapy (SACT), along with supplementary medicines, for pediatric patients with hematological malignancies in routine clinical practice globally to provide insights into current practice and identify gaps in the literature. A scoping review methodology, following the Joanna Briggs Institute guidance, was used to identify observational studies, published between January 2013 and February 2023 in PubMed, Embase, and Scopus databases. A total of 82 studies were identified, describing the use of 50 SACT agents and 74 supplementary care medicines. Findings highlighted the implementation of multi-drug therapeutic plans to treat hematological malignancies and the diversity of treatments across settings. Cancer treatment was commonly complemented by the administration of various supplementary medicines. Further observational studies should be conducted to provide additional insights into pharmacological interventions in under-researched therapeutic areas; in addition, descriptive drug utilization studies would be beneficial from clinical settings where pediatric cancer patients are commonly included in clinical trials to address knowledge gaps on treatments in these settings.

ORCID iDs

Alkhlaifat, Rahaf ORCID logoORCID: https://orcid.org/0000-0002-7007-3534, Madanat, Faisal ORCID logoORCID: https://orcid.org/0009-0008-6950-2208, Abunimeh, Hanan Nabeel, Weir, Natalie M. ORCID logoORCID: https://orcid.org/0000-0003-1422-9415 and Mueller, Tanja ORCID logoORCID: https://orcid.org/0000-0002-0418-4789;
CORE (COnnecting REpositories)